Page last updated: 2024-09-02

tamibarotene and Cutaneous T-Cell Lymphoma

tamibarotene has been researched along with Cutaneous T-Cell Lymphoma in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Egusa, C; Kato, Y; Maeda, T; Tsuboi, R1

Other Studies

1 other study(ies) available for tamibarotene and Cutaneous T-Cell Lymphoma

ArticleYear
Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
    Journal of dermatological science, 2016, Volume: 81, Issue:1

    Topics: Acetylation; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzoates; Cell Line, Tumor; Cell Proliferation; Female; Genes, Tumor Suppressor; Histone Deacetylase Inhibitors; Histones; Humans; Lymphoma, T-Cell, Cutaneous; Mice; Mice, Inbred NOD; Mice, SCID; Promoter Regions, Genetic; Pyridines; Receptors, Retinoic Acid; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes; Xenograft Model Antitumor Assays

2016